gdc
Breast CancerWeb Exclusives

Blood-Based Biopsy Can Predict Breast Cancer Recurrence

In patients with HR-positive breast cancer, a positive circulating tumor cells assay result was associated with nearly a 20-fold increased risk for recurrence of disease.

Web Exclusives

In the near future, a blood test that measures the number of tumor cells circulating in the blood, sometimes referred to as a “liquid biopsy,” may be used to predict the chance that breast cancer may recur. In a recent study, measuring circulating tumors cells (CTCs) in patients with metastatic breast cancer using a test cleared by the FDA (CELLSEARCH®) was found to be a biomarker that predicted late recurrence among patients with hormone receptor (HR)-positive, HER2-negative early breast cancer.

In this population of patients, late recurrences (defined as those that occur ≥5 years after initial diagnosis) account for approximately 50% of recurrences in HR-positive breast cancers, noted the study’s lead investigator Joseph A. Sparano, MD, Associate Director for Clinical Research, Montefiore Einstein Center for Cancer Care, Albert Einstein Cancer Center, New York, NY.

The results from this study provide “proof of concept” that the presence of CTCs is a biomarker for late recurrence of disease.

“To our knowledge, this is the first report showing that a liquid-based biomarker is robustly prognostic for late recurrence,” said Dr Sparano.

The data also support the concept that therapy for patients might be tailored based on the blood biomarker test results.

This study, the details of which were presented at the 2017 San Antonio Breast Cancer Symposium, included 546 patients drawn from a larger study that tested the effect of adding bevacizumab (Avastin) to chemotherapy as adjuvant treatment following surgery. The patients selected had no recurrence of breast cancer 4.5 to 7.5 years after an initial diagnosis of HER2-negative stage II-III disease.

Thirty-five percent of patients who had blood samples were HR-negative. Eighty-eight percent of patients with estrogen receptor–positive disease were taking endocrine therapy at the time of their CTC sample. At a follow-up of 1.8 years, 4.0% of HR-positive patients and 0.5% of HR-negative patients had a breast cancer recurrence.

Overall, 4.8% of patients had a positive CTC assay result, including 5.1% of HR-positive patients and 4.1% of the HR-negative patients.

In the 353 patients with HR-positive disease, CTC-positive patients had a 21.7-fold higher risk for recurrence compared with the CTC-negative group. The median time to recurrence in CTC-positive patients was 1.6 years. A positive CTC assay was not associated with recurrence in the HR-negative group.

The results were somewhat unexpected, according to Dr Sparano. “We were surprised to see that 5% of patients had CTCs about 5 or more years after their initial diagnosis,” he said. “Although we were expecting that CTC-positive patients would have a higher recurrence rate, we weren’t expecting the risk of recurrence to be this high after a relatively short period of time.”

Further study is needed to confirm the clinical utility of this information, he added. For instance, it may be possible that patients can be spared extended adjuvant endocrine therapy if they have a negative CTC assay, indicating a low risk for recurrence.

Source:
Sparano JA, O’Neill A, Alpaugh K, et al. Circulating tumor cells (CTCs) five years after diagnosis are prognostic for late recurrence in operable stage II-III breast cancer. Presented at: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017. Abstract GS6-03.

Recommended For You
Breast Cancer
From Silent Voices to “Hear My Voice”: People Living with Metastatic Breast Cancer Are Speaking Out
By Martha Carlson, Catherine Ormerod
Advocacy program trains metastatic breast cancer patients to educate the public about the disease and helps them share resources with other patients.
Breast CancerCancer Biomarkers
What Are Biomarkers in Breast Cancer, and How Do They Affect My Treatment? – Interview with Daniel F. Hayes, MD, FACP, FASCO
In this interview, Dr. Daniel F. Hayes, MD, FACP, FASCO, Immediate Past President of ASCO and the Stuart B. Padno’s Professor of Breast Cancer Research at the University of Michigan Comprehensive Cancer Center talks about how biomarkers offer more precise treatment opportunities for breast cancer patients.
LeukemiaNewsworthyWeb Exclusives
Quizartinib Significantly Improves Survival Over Chemotherapy in Patients with Relapsed/Refractory AML and FLT3-ITD Mutation
This is the first treatment that targets patients with AML and the FLT3-ITD mutation. In this clinical trial, patients who received quizartinib lived longer without disease progression than those receiving chemotherapy.
MelanomaSlideshowsWeb Exclusives
Skin Cancer Awareness Month
May is Skin Cancer Awareness Month! View this slideshow to learn the latest statistics in the United States, leading causes and preventive measures, and quick facts on melanoma, one of the most common types of skin cancer. Conquer cancer with knowledge.
Last modified: March 21, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country